Calmodulin variants associated with congenital arrhythmia impair selectivity for ryanodine receptors

Giuditta Dal Cortivo1, Valerio Marino1, Silvia Bianconi1

  • 1Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Verona, Italy.

Insights

Calmodulin (CaM) regulates muscle contraction by binding to RyR1 and RyR2. This study reveals how CaM variants linked to arrhythmia disrupt this interaction, impacting muscle function.

Area of Science:

  • Biophysics
  • Molecular Biology
  • Cardiology

Background:

  • Calmodulin (CaM) is a crucial calcium sensor protein.
  • CaM regulates ryanodine receptors (RyR1 and RyR2) essential for muscle contraction.
  • Mutations in CaM can lead to congenital arrhythmias.

Purpose of the Study:

  • To investigate the molecular mechanisms of CaM interaction with RyR1 and RyR2.
  • To analyze the impact of arrhythmia-associated CaM variants (N97I and Q135P) on this interaction.

Main Methods:

  • Comprehensive biophysical investigation of protein-peptide interactions.
  • Assessment of structural, thermodynamic, and kinetic properties.
  • Molecular dynamics simulations for structural and topological analysis.

Main Results:

  • Identified key amino acids mediating allosteric processes for target selectivity.
  • Demonstrated that CaM's discrimination between RyR1 and RyR2 relies on kinetic factors.
  • Showed that CaM variants N97I and Q135P perturb allosteric communication and kinetic discrimination.

Conclusions:

  • CaM's precise regulation of RyR1 and RyR2 involves kinetic discrimination and allosteric communication.
  • Arrhythmia-associated CaM variants disrupt these mechanisms, potentially explaining their pathological effects.
  • Understanding these interactions is vital for developing therapies for muscle disorders and arrhythmias.

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.2K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.0K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
636
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
36
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.6K